Atuveciclib

阿图韦西尼

Atuveciclib

A658632-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9 / CycT1 with an IC 50 of 13 nM. Appearance:Solid IC50& Target:CDK9/CycT1 13 nM (IC 50 ) CDK9/CycT1(h) 6 nM (IC 50 ) CDK3/CycE(h) 890 nM (IC 50 ) CDK2/CycE(h) 1000 nM (IC 50 ) CDK1/CycB(h) 1100 nM (IC 50 ) CDK5/p35(h) 1600 nM (IC 50 ) In Vitro:Positive transcription elongation factor b (PTEFb) is a heterodimer of CDK9 and one of four cyclin partners, cyclin T1, cyclin K, cyclin T2a or cyclin T2b. Atuveciclib (BAY-1143572) demonstrates potent antiproliferative activity against HeLa cells (IC 50 In Vivo:In vivo efficacy studies in the MOLM-13 xenograft model in mice, Atuveciclib (BAY-1143572) demonstrates great potency and high antitumor efficacy. Daily administration of Atuveciclib (BAY-1143572) at 6.25 or 12.5mg/kg results in a dose-dependent antitumo Biological Activity:Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9 / CycT1 with an IC 50 of 13 nM.

C18H18FN5O2S

387.43 g/mol

N=[S@](CC1=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=CC=C1)(C)=O

DMSO : ≥ 128.5 mg/mL (331.67 mM)

包含CDK，MAPK，GSK3，CLK家族